Loading…
Based on limited metadata, CanaRx Services Inc., a drug-related company, received an FDA Warning Letter on February 26, 2019. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the precise compliance issues cited, the complete Warning Letter would need to be reviewed.